Estradiol pivalate/progesterone
combination drug
Estradiol pivalate/progesterone (ETMA/P4), sold under the brand name Estrotate with Progesterone, is a combination medication of estradiol pivalate (estradiol trimethylacetate; ETMA), an estrogen, and progesterone (P4), a progestogen, which was used in menopausal hormone therapy and the treatment of gynecological disorders but is no longer available. It contained 1 mg/mL ETMA and 10 mg/mL P4 in oil solution provided in vials and was administered by intramuscular injection at regular intervals.
ETMA/P4 was introduced for medical use by 1949. It was one of the first combined estrogen and progestogen medications to be marketed, and was followed by the more well-known estradiol benzoate/progesterone (brand name Duogynon) in 1950. Other similar estrogen–progestogen preparations were also subsequently introduced.
The public source identifies “Estradiol pivalate/progesterone” as combination drug. This brief keeps that definition visible, then builds a research path around Estradiol, pivalate and progesterone.
Why this record matters
A short description can identify a subject without explaining its stakes. For “Estradiol pivalate/progesterone”, the useful work is to connect “combination drug” to the records capable of establishing context and consequence.
The citation trail is more important than the brevity of the summary: it shows where individual claims can be examined in context. The source revision retrieved here is dated Dec 23, 2025. The linked authority identifier is Q64521864. None of the 0 selected statements returned an explicit reference. The first chronological checks are 1949 and 1950.
A concise general-reference account can conceal disagreements about scope, terminology or the weight assigned to individual sources. The lead is largely declarative, so disagreement and counter-evidence require a deliberate search beyond the opening account. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Use the entry as an orientation point, then follow its citations and revision history. Names, dates and institutional relationships should be checked against the original record.
- Subject orientation
- Search vocabulary
- Locating named sources
The closest primary source, responsible institution and strongest cited specialist reference.
Three-step research path
- Establish the record: confirm the title “Estradiol pivalate/progesterone”, its source revision and the description used here.
- Expand the search: follow Estradiol pivalate/progesterone primary sources, Estradiol pivalate/progesterone archive and Estradiol research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Estradiol pivalate/progesterone”?
- What terminology or title could unlock a more precise catalogue search?
- Which institution is responsible for the underlying evidence?
Search terms from this dossier
This entry incorporates text from “Estradiol pivalate/progesterone” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.